Balyasny Asset Management LLC Neoleukin Therapeutics, Inc. Transaction History

Balyasny Asset Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$10.17 - $14.56 $1.12 Million - $1.6 Million	-110,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$9.68 - $17.01 $387,200 - $680,400	40,000 Added 57.14%	110,000 $1.32 Million
Q2 2020 Aug 14, 2020	BUY	$9.95 - $17.05 $515,350 - $883,087	51,794 Added 284.49%	70,000 $1.16 Million
Q1 2020 May 15, 2020	SELL	$6.12 - $13.64 $505,053 - $1.13 Million	-82,525 Reduced 81.93%	18,206 $207,000
Q4 2019 Feb 14, 2020	BUY	$2.65 - $12.72 $266,937 - $1.28 Million	100,731 New	100,731 $1.24 Million

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.